Million Dollar Drugs
New drugs have hit the market that total well over one million or event two million dollars over the course of the treatment. While most drugs may be self-administered, this list of most expensive drugs does include several that are physician-administered. You can thank the research team at GoodRx for compiling this latest drug report. Their team compiles the most expensive drugs on a quarterly basis.
Also, Don’t ask us to spell or pronounce any of these drugs without heavy support from a dictionary.
|Drug||Annual cost based
on length of therapy
Top on the list is, Zolgensma. A prescription drug used to treat spinal muscular atrophy, a rare childhood disorder that causes muscular erosion that can lead to lung infections and muscle weakness.
Luxturna is a gene therapy that treats an inherited form of retinal dystrophy
Myalept is used to treat leptin deficiency in patients with generalized lipodystrophy, a condition of abnormal fat distribution in the body. This is the most costly self-administered prescription drug.
Folotyn is approved to treat peripheral T-cell lymphoma, a rare blood cancer that can cause death.
Soliris is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), blood disorders that result in the destruction of red blood cells.
Blincyto is used to treat a rare form of acute lymphoblastic leukemia, a cancer of the blood and bone marrow.
Ravicti is used to treat urea cycle disorders.
Lumizyme is used to treat Pompe disease, an inherited disorder that causes a buildup of complex sugars in the body that affects the liver, heart, and muscles, which leads to muscle weakness and trouble breathing.
Actimmune is approved to treat osteopetrosis and chronic granulomatous disease, rare disorders that cause the immune system to malfunction.
The last drug on this list is Takhzyro, and is used to treat hereditary angioedema, a condition that causes swelling in the limbs, face, intestinal tract, and airways.
What Do You Think?
Should drug companies be allowed to charge such high prices? Would lowering prices dis-incentivize companies from pursuing cures for incurable diseases?
There are a lot of questions to consider, we believe that greater transparency and driving public attention to the topic will help create a space for the community to become involved and hopefully land our communities and companies in a mutual position.